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Background: The prescription of fixed-dose combinations (FDC) of antihypertensive drugs has increased rapidly
since the relaxation of the prescription-term restriction.
In this study, we used the opportunity of this policy change in Japan as an instrument to assess the causal impact
of switching to FDC on hypertensive treatment costs.
Methods: Claims data from 64 community pharmacies located in Tokyo were used to identify hypertensive
patients under continuous treatment with angiotensin-receptor blockers (ARBs). Patients switching to FDC between
December 2010 and April 2011 were compared to patients who did not receive FDC (control group). Changes in
annual antihypertensive drug costs were compared using a difference-in-differences approach to adjust for patient
characteristics and use of concomitant medication. Subpopulation analyses were also performed, taking into
account pre-index treatment patterns and prescribers’ characteristics.
Results: There were 542 patients who switched to FDC and 9664 patients in the control group. No significant
differences were observed between the 2 groups, except for antihypertensive drug use patterns before the policy
change and prescribers’ characteristics. The switch to FDC was associated with an annual saving of 10,420 yen (US
$112.0) in antihypertensive drug costs. Approximately 20% of the FDC patients, however, switched from ARB alone,
and their drug costs increased by 2376 yen (US$25.5).
Conclusions: For hypertensive patients who required ARB-based combination therapy, switching to FDC drugs had
a significant cost-saving effect. However, the policy change of relaxing the prescription-term restriction could
encourage aggressive treatment, i.e., switching to a combination therapy from monotherapy, regardless of medical
conditions. Further research is required to evaluate the possible negative aspects of FDC drugs.
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SwitchingBackground
Aggressive antihypertensive treatment using a combination
therapy that includes drugs with different mechanisms of
action has been recommended as a means of achieving
better blood pressure control [1-3]. Reflecting the clinical
evidence, including the findings of the ACCOMPLISH
study [4], an angiotensin-receptor blocker (ARB) together
with a calcium-channel blocker (CCB) is the combination
most frequently prescribed to Japanese hypertensive* Correspondence: makazawa@my-pharm.ac.jp
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distribution, and reproduction in any mediumpatients [5,6]. For patients who have comorbidities such as
hyperlipidemia, diabetes, and chronic renal disease, more
aggressive treatment, with the addition of thiazide diuretics
(i.e., hydrochlorothiazide or HCTZ) is provided to achieve
therapeutic goals [7]. Because those patients need to take
multiple medications in a day, the complex regimen often
affects the patients’ adherence to the treatments. Thus,
fixed-dose combination (FDC) therapy becomes one
option. Many studies suggested that simplifying drug regi-
mens by reducing the number of pills may improve patient
adherence, lower blood pressures, and save health serviced Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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example, a yearly estimated cost-saving of $27 to $45
million could be made when 60–100% of patients who had
received 2 separate antihypertensive drugs switched to
FDC products [16]. On the other hand, many antihyper-
tensive drugs are available as generic formulations, while
most FDC products are available as brand-name drugs
alone. In the United States, where generics have the biggest
market share in the world, observational studies using vari-
ous databases indicated that the pharmacy cost of treating
hypertension would increase after a switch to FDC prod-
ucts [11,14,17]. This increase cannot be ignored from the
patients’ perspective, because their out-of-pocket costs vary
according to their insurance status [18].
Since 2006, FDC pills that include ARB+HCTZ or
ARB+CCB have been introduced to the Japanese market.
By reflecting Japanese health policy to control drug
expenditures by achieving a 30% market share in volume
with generic drugs, the FDC pills were also expected to
bring economic benefits [19,20]. Reimbursement prices
(Yakka) of the FDC pills were set at 80% of the total
prices of the individual drugs available in the market,
where only branded ARBs were available [21]. The prices
of the FDC antihypertensive drugs and their original
drugs listed by the National Health Insurance (NHI)
authority are summarized in Table 1. According to the
list, by considering the cheapest combination, the daily
price of ARB and HCTZ changes from 120.4 yenTable 1 NHI price list of antihypertensive drugs
Drug name
ARB+HCTZ FDC losartan (50 mg) + hydrochlorothiazide (6.25 mg)
valsartan (80 mg) + hydrochlorothiazide (6.25 mg)
candesartan (8 mg) + hydrochlorothiazide (6.25 mg)
telmisartan (40 mg) + hydrochlorothiazide (6.25 mg)
ARB+CCB FDC valsartan (80 mg) + amlodipine (5 mg)
olmesartan (20 mg) + azelnidipine (16 mg)
candesartan (8 mg) + amlodipine (5 mg)
telmisartan (40 mg) + amlodipine (5 mg)





HCTZ hydrochlorothiazide (25 mg)
CCB amlodipine (5 mg)
azelnidipine (16 mg)
ARB: angiotensin-receptor blocker, CCB: calcium-channel blocker, FDC: fixed-dose co
This table created from the NHI Drug Price List as of April 2012. When various dose
selected. A generic version of losartan was listed in June 2012 at a price of 86.0 yen(valsartan + hydrochlorothiazide) to 120.9 yen (their
FDC) and that of ARB and CCB changes from 137.9 yen
(valsartan + amlodipine) to 120.3 yen (their FDC). How-
ever, since the market share of generic drugs (including
HCTZ and CCB) is still low in Japan compared with
other developed countries, while prescribers may recon-
sider their hypertensive treatment strategy when they
prescribe an FDC, the impact on actual treatment costs
of switching to the FDC drugs is uncertain and needs to
be evaluated using real-world clinical data.
In Japan, newly listed drugs can be prescribed only in
quantities sufficient for 14 days’ treatment [22]; therefore,
patients have to visit their doctors repeatedly to get their
prescriptions. This dispensing-day restriction is removed
1 year after launch, except for narcotic and psychotropic
drugs. In a survey of 490 Japanese doctors, over 80%
responded that the 14-day dispensing rule influences their
choice of treatment [23]. Considering their patients’ in-
convenience, doctors often hesitate to prescribe new med-
ications if there are other options, especially when they
are treating conditions that require continuous manage-
ment, such as hypertension. Thus, the market penetration
of new drugs can be somewhat limited by this restriction.
In the case of FDC drugs, however, Japan’s Central Social
Insurance Medical Council (Chuikyo) decided that, be-
cause the clinical experience of each individual drug was
sufficient, the14-day dispensing rule could be relaxed [24]


















s of combination drugs exist, a major combination that is used frequently was
for a 50 mg tablet, about 60% of the cost of the original drug.
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December 10, 2010. This policy change appeared likely to
influence doctors’ prescribing behavior, so that the num-
ber of prescriptions of FDC drugs would increase rapidly
immediately after this restriction was removed. In some
cases, doctors might switch antihypertensive drugs regard-
less of medical conditions that required more aggressive
treatments to control blood pressure.
In many previous studies that evaluated the benefits of
FDC drugs, annual medical and drug costs were com-
pared in patients who used FDC drugs and those with-
out FDC drugs. To minimize potential selection bias,
patient background characteristics were adjusted using
propensity score and/or multivariable regression tech-
niques [9,13,15,17]. Because limited information is avail-
able in healthcare databases, unobservable confounding
cannot be eliminated. Therefore, using this policy
change in Japan as an instrument that would be en-
dogenous for doctor preference and patient case-mix,
we tested the hypothesis that switching to FDC drugs
actually reduces antihypertensive drug costs, using a real
world prescription record in Japan.
Methods
Data source
Nihon Chouzai is a large community pharmacy chain that
has 457 dispensing pharmacies throughout Japan. We
used its pharmacy claims database to extract data for pa-
tients who were prescribed ARBs continuously (i.e., who
had dispensing records of an ARB at least every 4 months
between December 2009 and March 2012) from pharma-
cies located in the Tokyo area (64 branches). The informa-
tion stored in the database includes anonymous
identification codes of patients, pharmacies, and institu-
tions; patients’ age and gender; dispensing date; drug
name (brand and general names, and unique identification
code, called the “YJ code”); and drug price, dose, and dur-
ation (dispensing days).
Study population and design
The relaxation of the 14-day dispensing rule for newly
listed FDC drugs started on December 10, 2010. Therefore,
on the assumption that hypertensive patients visit the
pharmacy at least once every 4 months for their continu-
ous treatment, a 4-month time window (from December
10, 2010 to April 10, 2011) was set to capture patients who
switched antihypertensive drugs in response to the policy
change (Figure 1). We identified patients who started tak-
ing fixed-dose ARB+HCTZ or ARB+CCB drugs during
this time window; these were designated as cases. Patients
who did not have dispensing records of FDC drugs but
were taking an ARB were assigned to the control group.
For both cases and controls, the first date within the time
window on which the FDC drug or ARB was dispensedwas set as the index date. Patients who started FDC ther-
apy before or after the time window or who did not have
any record of ARB dispensing were excluded from the
study population.
Variables
The main outcomes of interests were the annual antihy-
pertensive drug costs before and after the index date. The
drug costs were summed over the 1-year interval prior to
the index date (as pre-index costs) and over the 1-year
interval after the index date (as post-index costs), includ-
ing all prescriptions dispensed within the respective inter-
vals. The annual costs were then calculated by adjusting
for differences between 365 days and the actual follow-up
days from which the costs were derived. Antihypertensive
drugs included were ARBs, angiotensin-converting en-
zyme (ACE) inhibitors, dihydropyridine CCBs, thiazide di-
uretics (HCTZ), beta-blockers, alpha-beta blockers, and
the FDC drugs. The study design is illustrated in Figure 1,
which shows an example of how the timeframe was de-
fined. Information about gender, age categories (≤64 years,
65–74 years, and ≥75 years), the number of drugs taken
(use of ≥7 drugs), use of a diabetes drug, and use of a
hyperlipidemia drug was extracted from the prescription
records during the 4-month time window to create vari-
ables that would represent the patients’ background char-
acteristics. As for prescribers’ characteristics, institutions
where the prescriptions at the index date were issued were
classified into 2 and variables indicating clinic (no bed) or
hospital, as well as cardiovascular specialists or others,
were created.
Analysis
The prescription pattern of the FDC drugs was summa-
rized as the ratio of the FDC prescriptions per month to
the total ARB prescriptions (including FDC drugs) per
month. A comparison of the patient characteristics (χ2 test)
and annual antihypertensive drug costs (t-test) was made
between the FDC drug users and the controls. Among the
FDC drug users, the patients who switched from ARBs
alone, those who had been taking both ARB and CCB in
separate forms, those whose drugs were prescribed by doc-
tors at clinics, and those whose drugs were prescribed by
cardiovascular specialists, were selected as subgroups to
compare the changes in antihypertensive drug costs.
Because the dispensing fees paid to doctors by the NHI
are based on the number of drugs prescribed, we evalu-
ated the association between taking ≥7 drugs and
switching to FDC drugs. Dispensing fees are discounted
when ≥7 drugs are prescribed at the same time, as a
disincentive to polypharmacy [25].
Changes in the drug costs among the FDC drug users
were compared with changes among the non-FDC drug
users (controls) using a difference-in-differences (DID)
Figure 1 Study design. Cases were defined as patients who started taking fixed-dose combination (FDC) drugs within the time window. The
index date was defined as the date of first prescription within the time window of FDC for cases and of ARB for controls. The total and
antihypertensive drug costs were calculated before and after the index date and were compared in cases and controls. A difference-in-differences
(DID) approach was used to estimate the effect on annual costs of switching to FDC drugs.
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to FDC drugs) on drug costs (δ) was estimated by the
following equation.
δ ¼ COSTpostindexcase  COSTpreindexcase
 
 COSTpostindexcontrol  COSTpreindexcontrol
 
Estimated costs were expressed in yen (1 US$ = 93
yen as of February 14, 2013).
The impact of patient characteristics, including gender,
age categories, number of concomitant drugs taken,
diabetes treatment, and hyperlipidemia treatment, was ad-
justed using a multivariable regression method. The level
of statistical significance was set at 5%. All statistical ana-
lyses were performed using SAS software version 9.3 (SAS
Institute Inc., 2012, Cary NC USA). The study was
approved by the Institutional Review Board at Meiji
Pharmaceutical University (study number 2305) and was
conducted in compliance with the Japanese Ethical Guide-
lines for Epidemiological Research, as updated in December
2008 [27].
Results
From the database we identified 11,993 hypertensive
patients who received ARB prescriptions regularly for 2 -
years from 64 pharmacies located in Tokyo. The number
of prescriptions for ARBs (including FDC drugs) was
fairly constant, varying mainly between 7000 and 8000
per month, during the follow-up period (Figure 2). Dur-
ing that period, the ratio of FDC prescriptions to total
ARB prescriptions increased rapidly, especially during
the time window, from 10% in December 2010 to 15% in
April 2011.To evaluate the impact on drug costs of switching to
FDC drugs, patients who started FDC therapy before
and after the time window (n = 1765) and those who
had no ARB prescription records during the time
window (n = 22) were excluded (Figure 3). The eligible
study population was then 10,206, comprising 542 cases
who switched to FDC drugs and 9664 controls who did
not. Among the 542 cases, 243 received fixed-dose ARB
+HCTZ and 302 received fixed-dose ARB+CCB, includ-
ing duplicated cases.
The characteristics of the cases and controls are sum-
marized in Table 2. Gender and age were similarly dis-
tributed in the 2 groups. Cases were more likely to have
been taking ARB and CCB combination therapy before
the index date (74.7% vs. 54.5%) and controls were more
likely to use ARB alone (40.7% vs. 19.2%). More switches
occurred when prescriptions were issued by doctors at
clinics (20.5% vs. 10.3%) and by cardiovascular specialists
(31.7% vs. 25.4%). No differences were observed in the
numbers of concomitant drugs, or in the use of drugs for
diabetes or hyperlipidemia. According to the prescription
pattern illustrated in Figure 4, the majority of hypertensive
patients were treated with ARBs and dihydropyridine
CCBs, as expected. However, for the cases, the proportion
of these drugs was dramatically reduced after the index
date as they were replaced by the FDC drugs.
Annual drug costs before and after the index date are
summarized in Figure 5. Among controls, drug costs
slightly decreased (by 1% or 589 yen) after the index
date, while large savings were observed (by 14% or
10,999 yen) for patients who started taking FDC drugs
(cases). In order to investigate these changes further, we
selected subpopulations according to the pre-index
Figure 2 Changes in prescription pattern during the study period. The dotted line indicates the ratio of FDC drugs to the total ARB
prescriptions and the solid line indicates the number of ARB prescriptions (including FDC drugs) per month. A 4-month time window from
December 2010 to April 2011 was set to capture FDC switching after the policy change relaxing the prescription-term restriction.
Akazawa and Fukuoka BMC Health Services Research 2013, 13:124 Page 5 of 9
http://www.biomedcentral.com/1472-6963/13/124treatment patterns—patients treated with combined
ARB and CCB in separate forms (n = 405) and those
treated with ARB alone (n = 104) —as well as pre-
scribers’ characteristics—doctors at clinics (n = 111) and
cardiovascular specialists (n = 172). Statistically signifi-
cant cost-savings were observed for patients switching
from the combination therapy of ARB and CCB (by 17%
or 14,079 yen), prescribed by doctors at clinics (by 15% or
10,132 yen), and by specialists (by 13% or 11,684 yen). On
the other hand, the annual drug costs were increased for
patients switching from ARB alone to FDC therapy (by
5% or 2965 yen).
The changes in the costs were estimated using the DID
approach by adjusting for patient characteristics and con-
comitant medications (Table 3). For the study populationFigure 3 Flowchart showing the selection of the study population. AR
date was defined as the first prescription date of FDC or ARB during the was a whole, cost-saving effects were observed (10,420 yen
on average). In addition, statistically significant cost reduc-
tions were observed for the cases who switched from the
combination of ARB and CCB (12,800 yen on average),
prescribed by doctors at clinics (8815 yen on average), and
by cardiovascular specialists (11,081 yen on average).
However, for those who switched from ARB alone, a nega-
tive impact on costs (2376 yen increase on average) was
observed, though it was not statistically significant.
Discussion
This study provides evidence that switching to FCD
drugs reduces the annual cost of antihypertensive treat-
ments. In particular, for patients treated with a combin-
ation of ARB and CCB in separate forms, the estimatedB: angiotensin-receptor blocker, FDC: fixed-dose combination. Index
indow time.
Table 2 Patient characteristics
With fixed-dose combination drugs (cases) Without fixed-dose combination drugs (controls) p (χ2 tests)
Number of patients 542 9664
Gender 0.1735
Male 198 36.5% 3814 39.5%
Age category 0.2087
≤64 years 212 39.1% 3729 38.6%
65–74 years 153 28.2% 3047 31.5%
≥75 177 32.7% 2888 29.9%
Drug use before index <.0001
ARB and CCB combination 405 74.7% 5269 54.5%
ARB alone 104 19.2% 3938 40.7%
Number of concomitant drugs 0.4567
7 or more 74 13.7% 1214 12.6%
Diabetes drugs 0.0582
Users 153 28.2% 2379 24.6%
Hyperlipidemia drugs 0.8094
Users 236 43.5% 4157 43.0%
Prescribers’ characteristics
Doctors at clinics (no bed) 111 20.5% 993 10.3% <.0001
Cardiovascular specialists 172 31.7% 2457 25.4% 0.0011
ARB: angiotensin-receptor blocker, CCB: calcium-channel blocker.
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other hand, one-fifth of the patients switched from a
single ARB pill to the FDC drug during the time
window. This suggests that relaxing the 14-day dis-
pensing rule may trigger more aggressive treatment toFigure 4 Prescription patterns of antihypertensive drugs among case
angiotensin-receptor blocker, CCB: calcium-channel blocker, HCTZ: hydrochachieve better blood pressure control and could increase
annual drug costs in such cases by 2400 yen.
A number of studies have indicated that switching to
FDC drugs improves medication adherence [10,28-30].
However, we could not confirm this benefit usings and controls. ACE: angiotensin-converting enzyme, ARB:
lorothiazide
Figure 5 Antihypertensive drug costs before and after index date for various patient populations. ARB: angiotensin-receptor blocker, CCB:
calcium-channel blocker. Changes in antihypertensive drug costs were statistically significant at 1% (**) levels according to t-tests.
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the doctor’s office regularly and received medications
according to a schedule, the medication possession ratio
(MPR) —which is defined as the total days of supply of
drugs during the study period divided by the length of
the follow-up period and is often used to measure adher-
ence in claims-based studies [31] —was almost 100% for
most patients, regardless of whether they actually took
the medications as indicated or not. In April 2012, the
NHI reimbursement rule for dispensing fees was revised
in order to increase the pharmacists’ responsibility for
checking for unused drugs and adjusting the quantity of
drugs dispensed [25,32]. When patients receive medica-
tions only as necessary, the MPR method can be used to
monitor their medication adherence using the claims.
We assumed that doctors might have an incentive to
use the FDC drugs so as to reduce the number of medi-
cations. According to Japan’s NHI reimbursement rule,
doctor’s prescription fees are 400 yen for prescribing ≥7
drugs compared with 680 yen for prescribing ≤6 drugs.
We identified 12% of the study population who had a
prescription for ≥7 drugs. A sub-analysis targeting only
those patients (data not shown) showed that theTable 3 Results of DID estimations of antihypertensive drug c
Estimate
Total patients n = 10,206 −10420
ARB and CCB combination before index n = 5674 −12800
ARB alone before index n = 4042 2376
Prescribed by doctors at clinics n = 1104 −8815
Prescribed by cardiovascular specialists n = 2629 −11081
Difference-in-differences (DID) estimates were obtained by adjusting for gender, ag
drug users. Antihypertensive drug costs were calculated by sum of reimbursement
inhibitors, dihydropyridine calcium-channel blockers (CCB), thiazide diuretics, beta-bproportion who switched to FDC drugs and the impact
on drug costs were almost the same as in the total study
population. This finding suggests that doctors do not
care about prescription fees; therefore, the switch may
occur regardless of the number of medications that are
prescribed at the same time.
The change in the dispensing rule encouraged the use
of an FDC drug. Due to the NHI pricing rule for ARB
combination drugs (approximately 80% of the individual
drugs), for most patients the switch resulted in a cost
saving. However, some cases switched from treatment
with ARB alone, resulting in an increased cost. If these
prescription changes occurred due to promotion of the
new drugs, rather than to medical need, the economic
benefits of switching need to be examined with care. It
should also be noted that a generic version of the ARB
losartan was introduced in June 2012 at prices 45%
below those of the corresponding branded medication
(45.3 yen for 20 mg, 86.0 yen for 50 mg, and 129.0 yen
for 100 mg). Under Japanese dispensing rules, generics
can be dispensed by pharmacists without the doctor’s
permission, unless the prescription form specifies that
there should be no generic substitution [33]. However,osts






e category, number of drugs (≥7), diabetes drug users, and hyperlipidemia
costs for angiotensin-receptor blockers (ARB), angiotensin-converting enzyme
lockers, alpha and beta-blockers, and fixed-dose combination drugs.
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to generics is unlikely, because the pharmacist would
need to ask the doctor to rewrite the prescription to
show the ARB and other medication separately before
dispensing the generic substitutions—a rather unrealistic
scenario. Thus, as our estimates suggest that the max-
imum cost saving from switching to FDC drugs was
17%, greater savings can be expected if patients continue
to use separate ARB and CCB medications and switch to
the generic forms when they become available. These
effects need to be monitored constantly using pharmacy
claims.
This social experiment examined the economic impact
of switching to FDC antihypertensive treatment in terms
of the benefit to the patient. However, because some pa-
tients actually switched to the aggressive treatment be-
cause of their medical needs, the effects we observed
could be biased toward either direction. In addition, we
had access only to prescription records at community
pharmacies, whereas no clinical information, such as
diagnosis and blood pressure, was available. Thus, the
results should be adjusted for lifestyle diseases that
might influence the treatment costs, incorporating vari-
ables corresponding to the use of drugs for diabetes and
hyperlipidemia. Furthermore, patients may visit different
pharmacies to obtain their medications and this would
not have been apparent from the available pharmacy
data. However, because the MPR was calculated as 100%
for many patients, these misclassifications might be
negligible. The DID approach was used to evaluate the
effect of policy changes using claims data [34]. In addition,
we could adopt a time-series approach, using monthly re-
cords of claims to compensate for the inherent limitation
of unmeasured variables, especially targeting cases who
switched from ARB alone to the FDC drugs [35].Conclusions
There are economic benefits from using combination
pills when the switch occurs from combination therapy
with the same drugs in separate forms. However, the
introduction of the combination pills may result in
aggressive but unnecessary treatment. Further research
is needed to evaluate the economic impact of the com-
bination pills by considering the introduction of antihy-
pertensive generics in the future market.Abbreviations
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